Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
about
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Simeprevir and daclatasvir for ...... 1b and advanced liver disease.
@en
type
label
Simeprevir and daclatasvir for ...... 1b and advanced liver disease.
@en
prefLabel
Simeprevir and daclatasvir for ...... 1b and advanced liver disease.
@en
P2093
P2860
P50
P356
P1433
P1476
Simeprevir and daclatasvir for ...... 1b and advanced liver disease.
@en
P2093
Ashley Brown
Edmund Omoruyi
Ferenc Szalay
Giovanni B Gaeta
Isabelle Lonjon-Domanec
Lawrence Serfaty
Michael Schlag
Moises Diago
Peter Buggisch
Piero L Almasio
P2860
P304
P356
10.1111/LIV.13376
P577
2017-01-30T00:00:00Z